

---

## Physitrack - Short-term challenges

Redeye provides updated estimates and valuation following Physitrack's Q2 report. As anticipated, the quarter was softer, reflecting the impact of the strategic shift away from one-time upfront revenue, which dampened growth. Additionally, the cost base remains front-loaded in preparation for Champion Health's upcoming market expansion. However, the launch is expected to drive growth in the year's second half. Our new fair value range is SEK9-72 (SEK9-75) with a Base case of SEK30 (35).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Physitrack - Short-term challenges](#)